Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary
In a bid to bring joy and smiles to people’s faces, Apsara Ice Creams today announced the launch of a…
Author: Leif Kristoffersen
BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000
On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance…
TreeFrog Presents Data from Its Parkinson’s Cell Therapy Program
TreeFrog Therapeutics, a cell therapy development company with its leading Parkinson’s disease program, is presenting for the first time at…
AVAVA™ Announces the Launch of MIRIA™ at ASLMS 2024 the Energy-Based Medicine & Science Conference
AVAVA™, an innovative aesthetics company focused on becoming a portal to the future of skin vitality, today announces the official…
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to…
Get Ready to Elevate Your Chill Game with Evn’s New Hybrid Gummies!
Roll out the green carpet and get your taste buds ready for a delightful new twist in the world of…
A pioneering two-day workshop in Bangalore to understand how climate change and caste and gender discrimination can make infections harder to treat
The One Health Trust, funded by the World Health Organization and the British Academy, hosted a two-day workshop focused on…
Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine
Venus Remedies, one of India’s leading exporters of generic medicines in critical care segments, has further expanded the reach of…
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and…
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce…